Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jul 29;24(1):364.
doi: 10.1186/s12890-024-03184-6.

Serum stratifin measurement is useful for evaluating disease severity and outcomes in patients with acute exacerbation of interstitial lung disease: a retrospective study

Noriko Sakuma  1 , Mitsuhiro Abe  2 , Daisuke Ishii  2 , Takeshi Kawasaki  2 , Noriaki Arakawa  3 , Shinichiro Matsuyama  3 , Yoshiro Saito  3 , Takuji Suzuki  2 , Koichiro Tatsumi  2
Affiliations

Serum stratifin measurement is useful for evaluating disease severity and outcomes in patients with acute exacerbation of interstitial lung disease: a retrospective study

Noriko Sakuma et al. BMC Pulm Med. .

Abstract

Background: Serum levels of stratifin (SFN), a member of the 14-3-3 protein family, increase in patients with drug-induced lung injury associated with diffuse alveolar damage. Therefore, we hypothesised that SFN levels would be higher in those experiencing acute exacerbation of interstitial lung disease (AE-ILD). A secondary analysis was also planned to determine whether SFN levels could discriminate survival in those with AE.

Methods: Thirty-two patients with clinically stable ILD (CS-ILD) and 22 patients with AE-ILD were examined to assess whether high serum SFN levels were associated with AE-ILD and whether SFN levels reflected disease severity or prognosis in patients with AE-ILD.

Results: Serum SFN levels were higher in the AE-ILD group than in the CS-ILD group (8.4 ± 7.6 vs. 1.3 ± 1.2 ng/mL, p < 0.001). The cut-off value of the serum SFN concentration for predicting 90-day and 1-year survival was 6.6 ng/mL. SFN levels were higher in patients who died within 90 days and 1 year than in patients who survived beyond these time points (13.5 ± 8.7 vs. 5.6 ± 5.3 ng/mL; p = 0.011 and 13.1 ± 7.5 vs. 3.1 ± 1.9 ng/mL; p < 0.001, respectively) in the AE-ILD group. When this cut-off value was used, the 90-day and 1-year survival rates were significantly better in the population below the cut-off value than in those above the cut-off value (p = 0.0017 vs. p < 0.0001).

Conclusions: High serum SFN levels are associated with AE-ILD and can discriminate survival in patients with AE-ILD.

Keywords: Acute exacerbations; Biomarker; Interstitial lung disease; Stratifin.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests. NA and YS are inventors of patents related to stratifin involved in the diagnosis of ILD as filed by the National Institute of Health Science.

Figures

Fig. 1
Fig. 1
Serum levels of stratifin (SFN). The values in patients with clinically stable interstitial lung disease (CS-ILD) and acute exacerbations of interstitial lung disease (AE-ILD) are shown. Each dot represents an individual in each group
Fig. 2
Fig. 2
Serum levels of stratifin in patients who survived and died after > 90 days. Each dot represents an individual in each group
Fig. 3
Fig. 3
Serum levels of stratifin in patients who survived and died after > 1 year. Each dot represents an individual in each group
Fig. 4
Fig. 4
Receiver operating characteristic (ROC) curves for optimal cut-off values for predicting 90-day survival. The values for serum SFN, lactate dehydrogenase (LDH), C-reactive protein (CRP), and brain natriuretic peptide (BNP) and the SpO2/FiO2 (S/F) ratio are shown
Fig. 5
Fig. 5
ROC curves for the optimal cut-off values for predicting 1-year survival. The values for serum SFN, LDH, CRP, and BNP and the S/F ratio are shown
Fig. 6
Fig. 6
Ninety-day survival rate. The 90-day survival rate is significantly higher in patients whose SFN values are below the cut off (< 6.6 ng/mL) than in those whose SFN values are above the cut off (≥ 6.6 ng/mL) (p = 0.0017). SFN: stratifin
Fig. 7
Fig. 7
One-year survival rate. The 1-year survival rate is significantly higher in patients whose SFN values are below the cut-off (< 6.6 ng/mL) than in those whose SFN values are above the cut-off (≥ 6.6 ng/mL) (p < 0.0001). SFN: stratifin
See this image and copyright information in PMC

References

    1. Collard HR, Ryerson CJ, Corte TJ, Jenkins G, Kondoh Y, Lederer DJ, et al. Acute exacerbation of idiopathic pulmonary fibrosis. An international working group report. Am J Respir Crit Care Med. 2016;194:265–75. 10.1164/rccm.201604-0801CI - DOI - PubMed
    1. Kondoh Y, Taniguchi H, Katsuta T, Kataoka K, Kimura T, Nishiyama O, et al. Risk factors of acute exacerbation of idiopathic pulmonary fibrosis. Sarcoidosis Vasc Diffuse Lung Dis. 2010;27:103–10. - PubMed
    1. Cottin V, Wollin L, Fischer A, Quaresma M, Stowasser S, Harari S. Fibrosing interstitial lung diseases: knowns and unknowns. Eur Respir Rev. 2019;28:180100. 10.1183/16000617.0100-2018 - DOI - PMC - PubMed
    1. Raghu G, Remy-Jardin M, Richeldi L, Thomson CC, Inoue Y, Johkoh T, et al. Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: an Official ATS/ERS/JRS/ALAT clinical practice guideline. Am J Respir Crit Care Med. 2022;205:e18–47. 10.1164/rccm.202202-0399ST - DOI - PMC - PubMed
    1. Suzuki A, Kondoh Y, Brown KK, Johkoh T, Kataoka K, Fukuoka J, et al. Acute exacerbations of fibrotic interstitial lung diseases. Respirology. 2020;25:525–34. 10.1111/resp.13682 - DOI - PubMed